Keeping Track Of Oncology: US FDA Approves Herceptin Hylecta, Reviews Darolutamide And Pexidartinib
Oncology news and highlights from our US FDA Performance Tracker.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
US FDA still deliberating on how best to measure success of the liver safety program for Daiichi's TGCT treatment, but REMS will probably assess both process and outcomes.
Erleada is ninth product known to be using US FDA’s Real-Time Oncology Review pilot program, as shown in our comprehensive chart.